New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

In a recent regulatory review, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard ...

Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, has ...

Premier Doug Ford called the expansion of Eisai Inc. in Mississauga “a major milestone in strengthening our plan to build ...

Eisai Limited was established in Canada in 2011 and is one of more than 40 subsidiaries of global, industry-leading, Eisai Co., Ltd. Rooted in Eisai's focus on delivering human health care (hhc ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

Eisai shares opened 0.2% lower on June 19, the day NICE announced its final decision. The US stock market, where Eli Lilly is listed, had not yet opened at the time of writing.

Eisai's digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed at improving the management of dementia. The smartphone app ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages. | In a quarterly update, the FDA said it’s evaluating the need for ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Eisai has a long history of developing drug therapies for dementia, starting with the cholinesterase inhibitor Aricept (donepezil) which was approved for Alzheimer's disease in the 1990s and ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...